Proprotein convertase subtilisin/Kexin type 9 (PCSK9) inhibitors have been confirmed to lower Lp(a) and should be considered as an independent treatment after acute coronary syndrome [24, 25]. This evidence concerns the gene PCSK9 and acute coronary syndrome.